Risk factor
Fair trading liquidity
Profitability factor
Very low or no dividends
About
Beijing Centergate Technologies (holding) Co., Ltd. is a multifaceted corporation with a presence in both domestic Chinese and international markets. Its principal activities include the manufacturing and distribution of pharmaceuticals, undertaking construction projects, developing real estate, and providing property management services. The company's pharmaceutical division offers a diverse range of medicinal products, such as huasu west-ground iodine, fesser phenylcycline hydrochloride, bosu fuma acid bisolol, yuanji beni flat hydrochloric acid, and naloxone hydrochloride, along with various tablets and capsules like five plus biochemical and aramol quramado. In addition to traditional medicines, Beijing Centergate Technologies produces specialized oral and mucous membrane repair and health products, encompassing toothpaste, mouthwash, sprays, and dental equipment. These items are designed to address issues like ulcers, burns, mechanical damage, and support post-operative healing. Furthermore, the company supplies nutritional products and food-grade raw materials, including fruit enzymes, imported fungella enzymes, beneficial probiotics, and soda. Beyond its operational segments, the firm also allocates investments to high-tech sectors such as software, communications and electronic engineering, biomedicine, and other areas within the life sciences. Established in Beijing, China, in 1999, the company remains headquartered in its founding city.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA,